Modalis Therapeutics
Emerging biotech company that develops therapeutics using CRISPR based technology.
Launch date
Employees
Market cap
AUD46.6m
Enterprise valuation
AUD33m (Public information from Sep 2024)
Share price
JPY103 4883.T
Cambridge Massachusetts (HQ), Tokyo Japan (founding location)
Financials
Estimates*
| JPY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 645m | 342m | 1.1m | 40.5m | - | 214m |
| % growth | - | (47 %) | (100 %) | 3582 % | - | - |
| EBITDA | 164m | (341m) | (1.2b) | (1.6b) | (2.3b) | - |
| % EBITDA margin | 25 % | (100 %) | (104567 %) | (3904 %) | - | - |
| Profit | 141m | (448m) | (739m) | (2.7b) | (2.4b) | - |
| % profit margin | 22 % | (131 %) | (67178 %) | (6673 %) | - | - |
| EV / revenue | - | 168.4x | 11651.8x | 168.8x | - | - |
| EV / EBITDA | - | -169.1x | -11.1x | -4.3x | -1.0x | - |
| R&D budget | 304m | 532m | 1.0b | 1.9b | 2.1b | - |
| R&D % of revenue | 47 % | 156 % | 91775 % | 4597 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$530k | Seed | ||
| N/A | JPY900m | Early VC | |
* | $4.2m | Series A | |
$15.0m | Series A | ||
$15.0m | Series B | ||
* | N/A | N/A | IPO |
| Total Funding | AUD64.4m | ||
Related Content
Recent News about Modalis Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.